Abstract
Flesinoxan hydrochloride has been shown in pharmacological experiments to be a potent and selective 5-HT1A receptor agonist with centrally-mediated antihypertensive properties. Flesinoxan lowers blood pressure in various species, and the effect lasts for more than four hours after a single administration [1]. The cardiovascular profile of the compound includes a reduction of total peripheral resistance, a small, vagally mediated decrease in heart rate, little or no effect on cardiac output, no direct negative inotropic effect and strong renal vasodilatation. Further, no orthostatic hypotension or tachyphylaxis has been found [1, 2]. In the investigation reported here flesinoxan has been studied in normotensive and hypertensive human subjects. Special attention was paid to cardiovascular parameters, safety, tolerability, psychometric performance and pharmacokinetics of the drug after single and repeated doses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hartog J, Wouters W (1988): Flesinoxan hydrochloride. Drugs of the future 13: 31–33.
Wouters W, Hartog J, Bevan P (1988): Flesinoxan. Cardiovasc. Drug Reviews 6: 71–83.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
de Voogd, J.M., Prager, G. (1990). Early clinical experience with flesinoxan, a new selective 5-HT1A receptor agonist. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_31
Download citation
DOI: https://doi.org/10.1007/978-94-009-0479-8_31
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6701-0
Online ISBN: 978-94-009-0479-8
eBook Packages: Springer Book Archive